Literature DB >> 32852559

Increased Risk of Squamous Cell Carcinoma of the Skin and Lymphoma Among 5,739 Patients with Bullous Pemphigoid: A Swedish Nationwide Cohort Study.

Zeyad Albadri1, Kristofer Thorslund, Henrike Häbel, Oliver Seifert, Carina Grönhagen.   

Abstract

Evidence about the association of bullous pemphigoid and the risk of cancer is conflicting. Patients diagnosed with bullous pemphigoid (n = 5,739) between 2005 and 2016 were matched with a control cohort from the general population (n = 17,168) to estimate their overall and specific risk of cancer. The risk of squamous cell cancer of the skin (cSCC) was increased in patients with bullous pemphigoid (hazard ratio (HR) 1.3; 95% confidence interval (CI) 1.1-1.6). The risk of lymphoma within one year after bullous pemphigoid diagnosis was also increased (HR 3.1; 95% CI 1.3-7.6). While overall cancer risk prior to diagnosis of bullous pemphigoid was similar in cases and controls (prevalence odds ratio (POR) 1.0; 95% CI 0.9-1.0), the risk of male genital cancer within one year prior to diagnosis of bullous pemphigoid was lower in cases (POR 0.4; 95% CI 0.2-0.8). Clinicians must be aware of the increased risk of cSCC and lym-phoma in patients with bullous pemphigoid.

Entities:  

Keywords:  autoimmune diseases; bullous pemphigoid; epidemiology; malignancy; skin diseases; cancer

Mesh:

Year:  2020        PMID: 32852559      PMCID: PMC9274914          DOI: 10.2340/00015555-3622

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  49 in total

1.  Cancer is not a risk factor for bullous pemphigoid: 10-year population-based cohort study.

Authors:  C T Chen; H Y Hu; Y T Chang; C P Li; C Y Wu
Journal:  Br J Dermatol       Date:  2018-10-17       Impact factor: 9.302

Review 2.  Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid.

Authors:  Erkan Alpsoy; Ayse Akman-Karakas; Soner Uzun
Journal:  Arch Dermatol Res       Date:  2015-01-15       Impact factor: 3.017

3.  Coexistence of malignancies with bullous pemphigoid.

Authors:  T P Chorzelski; S Jablonska; E Maciejowska; E H Beutner; L Wronkowski
Journal:  Arch Dermatol       Date:  1978-06

Review 4.  Pemphigoid and cancer.

Authors:  B Lindelöf; N Islam; G Eklund; L Arfors
Journal:  Arch Dermatol       Date:  1990-01

5.  Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study.

Authors:  Outi Varpuluoma; Anna-Kaisa Försti; Jari Jokelainen; Miia Turpeinen; Markku Timonen; Laura Huilaja; Kaisa Tasanen
Journal:  J Invest Dermatol       Date:  2018-02-07       Impact factor: 8.551

6.  A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid.

Authors:  J C Delgado; D Turbay; E J Yunis; J J Yunis; E D Morton; K Bhol; R Norman; C A Alper; R A Good; R Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

Review 7.  Ultraviolet radiation and skin cancer.

Authors:  Deevya L Narayanan; Rao N Saladi; Joshua L Fox
Journal:  Int J Dermatol       Date:  2010-09       Impact factor: 2.736

Review 8.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

9.  Bullous pemphigoid and ovarian cystadenocarcinoma. Immunologic studies.

Authors:  M V Dahl; S Ristow
Journal:  Arch Dermatol       Date:  1978-06

10.  Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases.

Authors:  Efi Pasmatzi; Alexandra Monastirli; John Habeos; Sophia Georgiou; Dionysios Tsambaos
Journal:  Diabetes Care       Date:  2011-08       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.